Expression and activity of potassium ion channels in human prostate cancer.
Four normal and 79 human prostate cancer (Pca) specimens were examined, by immunohistochemistry, for expression of voltage-gated potassium ion channels. Strong immunostaining (for Kv1.3) was observed in the normal and 47% (37/79) of Pca specimens. Twenty-nine percent (23/79) Pca specimens showed moderate and 24% (19/79) displayed low staining. Three potassium channel-openers at a concentration of 10 microg/mL, minoxidil (47.8 microM), 1-Ethyl-2-benzimidazolinone (EBIO) (61.7 microM) and diazoxide (43.3 microM), increased growth of PC3 cells by 30-50%. Potassium channel-blockers, dequalinium, amiodarone and glibenclamide, caused a dose-dependent, growth inhibition of four human Pca cell lines. Apoptosis occurred within 4h of treatment of PC3 cells with dequalinium (0.5 microg/mL, 0.9 microM), amiodarone (5 microg/mL, 7.3 microM) or glibenclamide (50 microg/mL, 0.1mM).
Abdul
Mansoor
M
Rumbaugh-Goodwin Institute for Cancer Research, 1850 NW 69 Ave #5, Plantation, FL 33313, USA.
Hoosein
Naseema
N
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D003981:Diazoxide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007150:Immunohistochemistry; D051664:Kv1.3 Potassium Channel; D008297:Male; D008914:Minoxidil / Q000494:pharmacology; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D015221:Potassium Channels / Q000032:analysis* / Q000502:physiology; D024642:Potassium Channels, Voltage-Gated; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology
D000889:Anti-Arrhythmia Agents; C496973:KCNA3 protein, human; D051664:Kv1.3 Potassium Channel; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D008914:Minoxidil; D003981:Diazoxide